Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686931 | 0.82 | KCNN4 (0.48) | P2RX7ALDH1A1KCNN4 | |
| SCHEMBL5815858 | 0.79 | P2RX7 (0.81) | P2RX7KMT2AALDH1A1TRPA1SIGMAR1 | |
| SCHEMBL6357960 | 0.78 | P2RX7 (0.65) | P2RX7KMT2AALDH1A1TRPA1SIGMAR1 | |
| SCHEMBL5813523 | 0.78 | P2RX7 (0.65) | P2RX7KMT2AALDH1A1TRPA1SIGMAR1 | |
| SCHEMBL5815057 | 0.75 | P2RX7 (0.74) | P2RX7KMT2AALDH1A1TRPA1SIGMAR1 | |
| SCHEMBL6360839 | 0.75 | P2RX7 (0.62) | P2RX7KMT2AALDH1A1TRPA1SIGMAR1 | |
| SCHEMBL5816280 | 0.75 | P2RX7 (1.00) | P2RX7TRPA1SIGMAR1 | |
| SCHEMBL22114391 | 0.75 | LMNA (0.53) | P2RX7KMT2AALDH1A1IDO1LMNA | |
| SCHEMBL1648295 | 0.75 | BACE1 (0.58) | P2RX7HDAC6 | |
| SCHEMBL4403732 | 0.75 | P2RX7 (0.81) | P2RX7KMT2AALDH1A1LMNAHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | P2RX7 4147/4885KMT2A 1566/4885ALDH1A1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.